Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: R03AL07

Bevespi Aerosphere(glycopyrronium;formoterol fumarate dihydrate)

Pulmonary Disease, Chronic Obstructive

Marketing Authorisation Holder: AstraZeneca AB

EMA Authorisation: 18/12/2018

INN: glycopyrronium;formoterol fumarate dihydrate

Indication

Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bevespi Aerosphere — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.